Jump to content
Sclero Forums

Search the Community

Showing results for tags 'ssc'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 21 results

  1. Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis (SSc) skin. These data provide a comprehensive portrait of the SSc skin microbiome and its association with local gene expression. PubMed, Arthritis Res Ther, 2019 Feb 6;21(1):49. (Also see Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Type I interferon dysregulation in Systemic Sclerosis. Here we describe the evidence of Type I IFN dysregulation in SSc, revealed predominately by genetics and gene expression profiling. PubMed, Cytokine, 01/23/2019. (Also see Cytokines) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Effects of treatment with rituximab on microcirculation in patients with long–term systemic sclerosis. Rituximab improves microcirculation in long–term SSc and stabilization and reduced progression of microcirculation abnormalities were achieved. PubMed, BMC Res Notes, 2018 Dec 10;11(1):874. (Also see Biologic Agents and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Median neuropathy at the wrist (MNW) in patients with systemic sclerosis (SSc): two–year follow–up study. MNW commonly has high incidence in SSc patients and therefore, SSc patients should be followed up in both clinical and electrodiagnostic studies for MNW screening. PubMed, Reumatologia, 2018;56(5):294-300. (Also see Hand and Joint Involvement) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Potential occupational and environmental factors in systemic sclerosis (SSc) onset. Although the pathogenesis of scleroderma remains unclear, there is a marked correlation between the onset of SSc and certain environmental or occupational factors. PubMed, Ann Agric Environ Med, 2018 Dec 19;25(4):596-601. (Also see Causes of Scleroderma: Environmental) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Prevalence and Clinical Associations of Antiphospholipid Antibodies (aPL) in Systemic Sclerosis (SSc): New Data From a French Cross–Sectional Study, Systematic Review, and Meta–Analysis. In our SSc population, aPL positivity was associated with venous thrombosis and miscarriage and these data provide additional insights into the role of aPL in the vasculopathy observed in SSc. PubMed, Front Immunol, 2018 Nov 2;9:2457. (Also see Antiphospholipid Syndrome) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Analysis of serum macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase in systemic sclerosis (SSc). Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in healthy controls and systemic lupus erythematosus patients. PubMed, Clin Transl Immunology, 2018 Dec 6;7(12):e1042. (Also see Cytokines) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. A Potential Link Between Oxidative Stress and Endothelial–to–Mesenchymal Transition (EndMT) in Systemic Sclerosis (SSc). We identified studies investigating associations reactive oxygen species and EndMT highlighting a potential link between oxidative stress and EndMT in SSc. PubMed, Front Immunol, 2018 Sep 19;9:1985. (Also see Oxidative Stress) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Champion bagpiper's fingers turned BLACK and had to be amputated after he contracted gangrene which nearly killed him. A champion bagpipe player had to have all his fingers and toes amputated after he developed gangrene which nearly killed him. Mail Online, 09/21/2018. (Also see Gangrene and Amputation) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Treatment of small intestinal bacterial overgrowth (SIBO) in systemic sclerosis (SSc): a systematic review. For some SSc patients, antibiotics can eradicate SIBO and there is a paucity of data reporting the effectiveness of either prokinetics or probiotics in SSc. PubMed, Rheumatology (Oxford), 07/02/2018. (Also see Bowel Dysfunction) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. A Feasibility Study of a Novel Low Level Light Therapy (LTTT) for Digital Ulcers (DUs) in Systemic Sclerosis. LTTT for DUs is safe, feasible and well tolerated. There was an early tentative suggestion of treatment efficacy. PubMed, J Dermatolog Treat, 2018 Jun 4:1-30. (Also see Treatments for Digital Ulcers) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis (SSc). The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases. PubMed, Ann rheumatologist Dis, 05/31/2018. (Also see Interleukins and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Cardiac involvement in undifferentiated connective tissue disease (UCTD) at risk for systemic sclerosis (SSc) (otherwise referred to as very early–early systemic sclerosis): a TDI study. Our study shows that UCTD–risk–SSc patients show a previously unrecognized, mild biventricular systolic and diastolic dysfunction as compared to controls. PubMed, Clin Exp Med, 2018 May;18(2):237-243. (Also see Undifferentiated Connective Tissue Disease) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. Microbial and metabolic multi–omic correlations in systemic sclerosis (SSc) patients. Our data suggest that in SSc, intestinal microbiota is characterized by proinflammatory alterations subtly entwined with the metabolic state. PubMed, Ann N Y Acad Sci, 05/11/2018. (Also see Bowel Dysfunction) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  15. Challenges and strategies for coping with scleroderma: implications for a scleroderma–specific self–management program. Although the challenges experienced by patients with scleroderma are unique, findings from this study might help better understand patients' perspectives regarding coping and disease management for other chronic diseases as well. PubMed, Disabil Rehabil, 2018 May 9:1-10. (Also see Coping Strategies) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  16. Acute and chronic effects of two different intravenous iloprost (ILO) regimens in systemic sclerosis: a pragmatic non–randomized trial. ILO had an acute effect as assessed by power Doppler US and by contrast, an ILO chronic effect was not detectable before the following infusion in both treatment groups. PubMed, Rheumatology (Oxford), 05/03/2018. (Also see Inhaled Prostacyclin) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  17. The safety of iloprost (ILO) in systemic sclerosis in a real–life experience. Our data suggest that calcium channel blockers should be transitorily stopped while using ILO and that a pre–treatment approach might reduce or control adverse events. PubMed, Clin Rheumatol, 02/22/2018. (Also see Inhaled Prostacyclin (Iloprost, Ventavist)) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  18. The impact of malnutrition on quality of life in patients with systemic sclerosis. Standardized nutritional screening should routinely be conducted to identify the risk of malnutrition in order to enable an intervention with multimodal treatment. PubMed, Eur J Clin Nutr, 03/08/2018. (Also see Diet and Systemic Scleroderma and QOL with Scleroderma) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  19. Pulmonary arterial hypertension (PAH) in the setting of scleroderma (SSc) is different than in the setting of lupus: A review. This review highlights the differences between SSc–PAH and Lupus–PAH. PubMed, Respir Med, 2018 Jan;134:42-46. (Also see Pulmonary Hypertension) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  20. Factors associated with the 6–minute walk distance (6MWD) in patients with systemic sclerosis (SSc). During SSc, the 6MWD is independently associated with initial HR and HR variation; suggesting that pulmonary vasculopathy may have a greater impact than parenchymal involvement on functional limitation. PubMed, Arthritis Res Ther, 2017 Dec 15;19(1):279. (Also see Pulmonary Fibrosis Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  21. Corticosteroids (CS) in Myositis and Scleroderma. The extracutaneous features of systemic sclerosis are frequently treated with CS; however, high doses have been associated with scleroderma renal crisis in high-risk patients. Rheumatic Disease Clinics, 10/27/2015. (Also see Glucocorticoids, Steroids (Prednisone) Warnings for Scleroderma) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...